ID
42191
Beskrivning
Documentation part: Clinical evaluation & outcome evaluation A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative, Phase III Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusidate Ointment Applied Three Times Daily for 7 Days in the Treatment of Adult and Paediatric Subjects with Impetigo. ClinicalTrials.gov Identifier: NCT00133874 Other Study ID Numbers: TOC100224 Responsible Party: GlaxoSmithKline
Nyckelord
Versioner (3)
- 2016-06-27 2016-06-27 -
- 2021-04-13 2021-04-13 - Dr. rer. medic Philipp Neuhaus
- 2021-11-17 2021-11-17 -
Uppladdad den
13 april 2021
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Clinical evaluation & outcome evaluation Topical SB-275833 Ointment 1% For The Treatment Of Impetigo NCT00133874
Clinical evaluation & outcome evaluation Topical SB-275833 Ointment 1% For The Treatment Of Impetigo NCT00133874
Similar models
Clinical evaluation & outcome evaluation Topical SB-275833 Ointment 1% For The Treatment Of Impetigo NCT00133874
| C1402294 (UMLS CUI [1,2])
C1519215 (UMLS CUI [2])
C3640841 (UMLS CUI [1,2])
C3845108 (UMLS CUI [1,2])